Table 1. Summary of the included studies.
| Author, year | Method | Country | Stage | N(Q1,Q3) | Age(Q1,Q3, y) | Sex(Q1:M/F; Q3:M/F) | Chemotherapy | Mean total radiation dose |
|---|---|---|---|---|---|---|---|---|
| Geeta SN, 2006 | Retro 2004-05 |
India | II-IV | 32 51 |
57.5 55 |
Q1:26/6 Q3:37/14 |
Q1:40mg/m2,6cycles Q3:100mg/m2,2-3days,3cycles |
66-70Gy 33-35F |
| Ho KF, 2008 | Retro 2000-04 |
England | IVa | 24 27 |
Q1:33-40mg/m2,6cycles Q3:80-100mg/m2,3cycles |
60-70Gy 33F, 45 days |
||
| Huang DN, 2009 | RCT 2003-07 |
China | III~IVa | 33 32 |
43 41 |
Q1:24/9 Q3:20/12 |
QW:30mg/m2,7-8cycles Q3W:80mg/m2,3cycles |
50-76Gy 2Gy/F, 5 days/week |
| Uygun K, 2009 | Retro 2002-07 |
Turkey | III-IV | 20 30 |
71 53.2 |
Q1:40mg/m2,6cycles Q3:100mg/m2,3cycles |
66-70Gy 33-35F,2Gy/day |
|
| Kose F, 2011 | Retro 2007-09 |
Turkey | II-IV | 32 23 |
58 60 |
Q1: 26/6; Q3:18/5 |
Q1:30mg/m2 Q3:100mg/m2 |
50-70Gy 2Gy/day, 5days/week |
| Tsan DL, 2012 | RCT 2008-10 |
Taiwan | II-IV | 24 26 |
49 49.2 |
Q1:23/1 Q3:25/1 |
Q1:40mg/m2 Q3:100mg/m2 |
66Gy 2Gy/F, 5 days/week |
| Espeli V, 2012 | Retro 2002-09 |
Switzerland | I-IV | 40 54 |
65 58 |
Q1:32/8 Q3:43/11 |
Q1:40mg/m2,6cycles Q3:100mg/m2, 3cycles |
66-72Gy |
| Jagdis A, 2014 | Retro 2000-09 |
British | II-IVb | 45 28 |
51 49.5 |
Q1:35/10 Q3:15/13 |
Q1:40mg/m2 Q3:100mg/m2,3cycles | 66-70Gy 33-35F |
| Geiger JL, 2014 | Retro 2004-10 |
United States | III-IV | 53 51 |
61 53 |
Q1:25-30mg/m2 Q3:100mg/m2,3cycles |
60-70Gy 30-35F |
|
| Tao CJ, 2014 | Retro 2003-07 |
China | II-IVb | 73 81 |
P=0.351 | Q1:56/17 Q3:59/22 |
Q1:30-40mg/m2,5-7cycles Q3:80mg/m2,3cycles |
60-68Gy 30F, 2.27Gy/F |
RCT = randomised controlled trial; Retro = retrospective comparative study; Q1=weekly; Q3=three weekly; y=year; M=male; F=female; F=fraction.